miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Kong, Amanda Shen-Yee; Lai, Kok-Song; Lim, Swee-Hua Erin; Sivalingam, Sivakumar; Loh, Jiun-Yan; Maran, Sathiya

doi:10.3390/ijms23169001

Cited by 17 publications

(13 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-145-mediated antiatherosclerotic therapy has been reported before. , Compared with UTMD-mediated drug or inflammatory factors therapy, UTMD-mediated miRNA therapy provides a unique fine-tuning to more directly and efficiently target the biological pathways that drive AS. − miR-145 can simultaneously bind to and inhibit multiple target genes (such as the VSMCs differentiation genes Acta2 and Myh11 , the angiogenic factor VEGFA , and the pro-inflammatory cytokine- IL-16), thereby providing a mechanism to synchronize the regulation of the entire gene network.…”

Section: Resultsmentioning

confidence: 99%

Enhanced Local Delivery of microRNA-145a-5P into Mouse Aorta via Ultrasound-Targeted Microbubble Destruction Inhibits Atherosclerotic Plaque Formation

Deng

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) play a key role in the formation and rupture of atherosclerotic plaques. Previous studies have confirmed that microRNA-145 (miR-145) is involved in the phenotypic regulation of VSMCs and reduction of atherosclerosis. At present, seeking safe and effective gene delivery remains a key problem restricting the development of gene therapy. In recent years, ultrasound-targeted microbubble destruction (UTMD) has become a safe and effective transfection method that is widely used in the basic research of gene therapy for heart and tumor diseases. Here, we synthesized cationic microbubbles to encapsulate miR-145 and targeted their release into VSMCs in vitro and in vivo using ultrasound. The feasibility of this gene therapy was verified by fluorescence microscopy and an in vivo imaging system. The results showed that treatment with miR-145 delivered via UTMD considerably improved the gene transfection efficiency and promoted the contraction phenotype of VSMCs in vitro. In vivo, this treatment reduced the atherosclerotic plaque area by 48.04% compared with treatment with free miR-145. Therefore, UTMDmediated miRNA therapy may provide a new targeted therapeutic approach for atherosclerotic plaques.

show abstract

Section: Resultsmentioning

confidence: 99%

Enhanced Local Delivery of microRNA-145a-5P into Mouse Aorta via Ultrasound-Targeted Microbubble Destruction Inhibits Atherosclerotic Plaque Formation

Deng

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Studies have shown that miRNAs play important roles in the occurrence and development of several diseases ( 31 , 32 ). The changes in miRNA levels associated with cardiovascular diseases have attracted attention since they have significant diagnostic values ( 33 , 34 ).…”

Section: Discussionmentioning

confidence: 99%

Reductions in extracellular vesicle-associated microRNA-126 levels in coronary blood after acute myocardial infarction: A retrospective study

Yuan

Aili

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAcute Myocardial Infarction (AMI) is a kind of cardiovascular disease with high mortality and incidence. Extracellular vesicles (EVs) and microRNA-126 (miR-126) are known to play important role in the development and prognosis of several cardiovascular diseases. Therefore, this study aimed to investigate the changes in Extracellular vesicle (EV)-associated miR-126 levels in the coronary blood of patients with AMI to explore the relationship between miR-126 levels and AMI.Materials and methodsWe analyzed EV-associated miR-126 in the coronary blood of patients with AMI and stable coronary artery disease (SCAD) using quantitative reverse transcription polymerase chain reaction (qRT-PCR).ResultsWe tested the coronary blood of 20 patients with AMI and 20 with SCAD. The mean age of the patients was 58.8 ± 10.3 years and 32 (80%) were men. We observed that the EV-associated miR-126 levels were lower in patients with AMI [median = 0.13; interquartile range (IQR): 0.08–0.22] than in patients with SCAD (median = 0.37; IQR: 0.26–0.48) (P < 0.001). In addition, the levels of miR-126 were negatively associated with the Thrombolysis in Myocardial Infarction (TIMI) score (r = −0.66, P = 0.001).ConclusionReduction of EV-associated miR-126 levels in the coronary blood of patients with AMI may be involved in acute coronary thrombosis events.

show abstract

“…There is a growing interest in miRNA playing a role in coronary artery syndromes and in their potential diagnosis and prognosis role illustrated by numerous studies and reviews that covered this issue: Kumric et al [ 137 ], Guo et al [ 138 ], Theofilis et al [ 139 ], and Kong et al [ 140 ]. Some new and interesting information may be added to these descriptive reviews.…”

Section: Circulating Biomarkers Of Vulnerable Plaquesmentioning

confidence: 99%

Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature?

Chiorescu

Mocan

Buda³

et al. 2022

IJMS

View full text Add to dashboard Cite

Atherosclerosis and its clinical manifestations, coronary and cerebral artery diseases, are the most common cause of death worldwide. The main pathophysiological mechanism for these complications is the rupture of vulnerable atherosclerotic plaques and subsequent thrombosis. Pathological studies of the vulnerable lesions showed that more frequently, plaques rich in lipids and with a high level of inflammation, responsible for mild or moderate stenosis, are more prone to rupture, leading to acute events. Identifying the vulnerable plaques helps to stratify patients at risk of developing acute vascular events. Traditional imaging methods based on plaque appearance and size are not reliable in prediction the risk of rupture. Intravascular imaging is a novel technique able to identify vulnerable lesions, but it is invasive and an operator-dependent technique. This review aims to summarize the current data from literature regarding the main biomarkers involved in the attempt to diagnose vulnerable atherosclerotic lesions. These biomarkers could be the base for risk stratification and development of the new therapeutic drugs in the treatment of patients with vulnerable atherosclerotic plaques.

show abstract

miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Cited by 17 publications

References 66 publications

Enhanced Local Delivery of microRNA-145a-5P into Mouse Aorta via Ultrasound-Targeted Microbubble Destruction Inhibits Atherosclerotic Plaque Formation

Enhanced Local Delivery of microRNA-145a-5P into Mouse Aorta via Ultrasound-Targeted Microbubble Destruction Inhibits Atherosclerotic Plaque Formation

Reductions in extracellular vesicle-associated microRNA-126 levels in coronary blood after acute myocardial infarction: A retrospective study

Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature?

Contact Info

Product

Resources

About